Last updated: 11/07/2018 10:40:48
PGx: Exploratory meta-analysis of transcriptomics data from the SB681323 and prednisolone single dose biomarker study in COPD patients (IPI100477)
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: PGx: Exploratory meta-analysis of transcriptomics data from the SB681323 and prednisolone single dose biomarker study in COPD patients (IPI100477)
Trial description: PGx: Exploratory meta-analysis of transcriptomics data from the SB681323 and prednisolone single dose biomarker study in COPD patients (IPI100477)
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Joanna C Betts, Ruth J Mayer, Ruth Tal-Singer, Linda Warnock, Chris Clayton, Stewart Bates, Bryan E Hoffman, Christopher Larminie and Dave Singh..Gene expression changes caused by the p38 MAPK inhibitor dilmapimod in COPD patients: Analysis of blood and sputum samples from a randomized, placebo controlled clinical trial.Pharmacol Res Perspect.2014
Medical condition
Pulmonary Disease, Chronic Obstructive
Product
dilmapimod
Collaborators
Not applicable
Study date(s)
January 2011 to August 2012
Type
Not applicable
Phase
Not applicable
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2012-10-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website